GHRH-T44
GHRH-T44 is a synthetic peptide consisting of 44 amino acids. It is a stabilized analogue of the Growth Hormone-Releasing Hormone (GHRH), distinguished by the addition of a trans-3-hexenoic acid group at the N-terminus. Research investigates this modification for its ability to extend the peptide's stability and biological half-life while retaining affinity for GHRH receptors in the anterior pituitary. For Research Use Only. Not for human consumption.
GHRH-T44 is a synthetic growth hormone-releasing hormone analog with the molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S. It is structurally based on the full 44-amino-acid human growth hormone-releasing factor sequence and includes an N-terminal trans-3-hexenoyl modification. This modification has been studied for its ability to improve peptide stability by reducing susceptibility to enzymatic degradation, including degradation associated with dipeptidyl peptidase-IV (DPP-IV).
Research involving GHRH-T44 focuses on its interaction with growth hormone-releasing hormone receptors located on somatotroph cells of the anterior pituitary. In laboratory models, receptor binding has been associated with stimulation of endogenous growth hormone signaling and downstream evaluation of insulin-like growth factor 1 (IGF-1) response. Because this compound acts through the GHRH receptor pathway, it is commonly studied in relation to pulsatile growth hormone release patterns rather than direct growth hormone replacement.
A major area of investigation involves metabolic signaling, lipid metabolism, and body-composition-related research models. Studies have evaluated GHRH analogs for their effects on visceral adipose tissue, hepatic lipid markers, triglyceride regulation, and broader metabolic dysregulation pathways. These research applications make GHRH-T44 useful for studying the relationship between growth hormone axis modulation, lipolysis, and adipose tissue distribution in controlled non-clinical settings.
This product is supplied strictly for laboratory research and analytical use only. It is not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or clinical application.
References
Ferdinandi, E. S., et al. (2007). “Preclinical pharmacokinetics and metabolism of TH9507, a growth hormone-releasing factor analog, in mice, rats, dogs, and monkeys.” Journal of Endocrinology, 195(1), 1-14.
Makimura, H., et al. (2013). “Reduced growth hormone secretion is associated with increased visceral adiposity in healthy older adults.” The Journal of Clinical Endocrinology & Metabolism, 98(5), 2090-2097.
Stanley, T. L., et al. (2011). “Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.” The Journal of Clinical Endocrinology & Metabolism, 96(1), 150-158.